Figure 2 | Scientific Reports

Figure 2

From: A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

Figure 2

Summary of Anti-S IgG and Neutralizing Antibodies (nAb) at each visit (Per Protocol Population). GMEU Geometric mean ELISA unit, GMT Geometric mean titer. For each study vaccine, the GMEU of Anti-S IgG and GMT of nAbs and 95% CI were calculated by transforming to the original scale of log10-transformed mean and its two-sided 95% CI limits at each visit.

Back to article page